Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

COPD Awareness Month: Looking towards a cure

This month, we observe COPD Awareness Month — a time to educate on the disease while reflecting on how far we’ve come in terms of treatment, and how clinical research is the path to a cure. Chronic Obstructive Pulmonary Disease, or COPD, is the third leading disease-related cause of death in the United states. Nearly 16 million people are living with it, and many more may have it without knowing ...

Continue reading

How We Delivered 60% of All US Randomizations in a Recent Trial [Case Study]

Primary biliary cholangitis (PBC) is an autoimmune condition that causes progressive destruction of the bile ducts. Current treatment options focus on delaying progression and managing complications, but it can be difficult to live with the symptoms, like fatigue, itchy skin, and pain, as well.

Continue reading

Alzheimer’s Awareness Month: A time to focus on research

November is National Alzheimer’s Disease Awareness Month. It’s a month where we stop to think about the 5.8 million Americans living with Alzheimers, and how someone in the US develops the disease every 65 seconds. It’s a time to provide extra support to the more than 16 million Americans who perform the role of caregiver, devoting an estimated 18.5 billion hours of care to those with Alzheimer’s ...

Continue reading

We Asked 4,000 Patients about Clinical Trials: Here's What Matters Most [Webinar Recap]

Last week, Antidote’s Head of Partnerships, Lindsey Wahlstrom-Edwards, hosted a webinar in which she shared the results of our patient survey. In the survey, we asked nearly 4,000 patients and caregivers about their attitudes and opinions of clinical research to find out what matters most, and how we can better engage patients from all walks of life in medical research.

Continue reading

The New Rules for Clinical Trials Patient Engagement: An ERT Podcast

Recently, Antidote’s Director of Business Development, Rachel Lind, was featured on the fantastic ERT podcast, “Trial Better.” She and host Jason Eger, Director of Organizational Readiness at ERT, discussed the changing landscape of patient recruitment, the ways in which patients are becoming their own advocates, the importance of diversity in clinical trials, and reducing site burden through ...

Continue reading

[Webinar] We Asked 4,000 Patients about Clinical Trials: Here's What Matters Most

It’s no secret that recruiting patients for clinical trials can be a difficult endeavor. And, even when a trial meets its quotas and timelines, many still do not reflect real-world populations. So how can we better engage patients from all walks of life in medical research?

Continue reading

Learn About Precision Recruitment at SCRS 2019

We’re gearing up to head to Florida later this week for the SCRS Site Solutions Summit, the annual meeting that brings sites, sponsors, CROs, and regulators together to discuss the current state of clinical research and where we go from here. We’re looking forward to meeting some of the brightest in the business, and sharing best practices that can drive success for all.

Continue reading

Leadership Profile: An Interview with Antidote CFO Keith Lovell

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation.

Continue reading

Antidote Named Scrip Award Finalist for “Best Technological Development in Clinical Trials”

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

Continue reading

Putting patients at the center starts with trust

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series.

Continue reading

Get our latest posts in your inbox